METHOD OF EVALUATING CANCERIZATION DEGREE

(19)

(11)

EP 1 679 371 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.10.2012 Bulletin 2012/43

(45)	Mention of the grant of the patent:
	12.09.2012 Bulletin 2012/37

(21)	Application number: 04773361.3

(22)	Date of filing: 15.09.2004

(51)

International Patent Classification (IPC):

C12Q 1/68^(2006.01)

G01N 33/50^(2006.01)

(86)	International application number:
	PCT/JP2004/013879

(87)	International publication number:
	WO 2005/026353 (24.03.2005 Gazette 2005/12)

(54)	METHOD OF EVALUATING CANCERIZATION DEGREE VERFAHREN ZUR BEURTEILUNG DES VERKREBSUNGSGRADES PROCEDE POUR EVALUER LE DEGRE DE CANCERISATION

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

16.09.2003 JP 2003322823

(43)	Date of publication of application:
	12.07.2006 Bulletin 2006/28

(73)	Proprietors:
	Sumitomo Chemical Company, Limited Tokyo 104-8260 (JP) National Cancer Center Tokyo 104-0045 (JP)

(72)	Inventors:
	USHIJIMA, Toshikazu Chuo-ku,Tokyo 1040045 (JP) HAGIHARA, Atsushi Koto-ku, Tokyo (JP)

(74)	Representative: Duckworth, Timothy John
	J A Kemp 14 South Square Gray's Inn London WC1R 5JJ London WC1R 5JJ (GB)

(56)

References cited: :

WO-A-99/36082
JP-A- 2001 522 241

WO-A-03/076594

TSUNEISHI SYUICHI ET AL: "Serum depletion increases the neurofilament protein mRNA levels in a neuroblastoma cell line, GOTO" MOLECULAR BRAIN RESEARCH, vol. 17, no. 1-2, 1993, pages 119-128, XP002438619 ISSN: 0169-328X
CLARK E A ET AL: "THE DIFFERENTIAL ROLE OF PROTEIN KINASE C ISOZYMES IN THE RAPID INDUCTION OF NEUROFILAMENT PHOSPHORYLATION BY NERVE GROWTH FACTOR AND PHORBOL ESTERS IN PC12 CELLS" JOURNAL OF NEUROCHEMISTRY, vol. 57, no. 3, 1991, pages 802-810, XP009085566 ISSN: 0022-3042
BRUCE JENNIFER ET AL: "Methylation and expression of neurofilament genes in tissues and in cell lines of the mouse" MOLECULAR BRAIN RESEARCH, vol. 17, no. 3-4, 1993, pages 269-278, XP002426751 ISSN: 0169-328X
SATO N ET AL: "Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 13, 1 July 2003 (2003-07-01), pages 3735-3742, XP002318399 ISSN: 0008-5472
HAGIHARA ATSUSHI ET AL: "Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 23, no. 53, 27 September 2004 (2004-09-27), pages 8705-8710, XP002401272 ISSN: 0950-9232
JANSEN M. ET AL.: 'Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade Pan1Ns' CANCER BIOL. THER. vol. 1, no. 3, 2002, pages 293 - 296, XP002982491
UEKI T. ET AL.: 'Hypermethylation of multiple genes in pancreatic adenocarcinoma' CANCER RES. vol. 60, no. 7, 2000, pages 1835 - 1839, XP001026187
ESTELLER M. ET AL.: 'A gene hypermethylation profile of human cancer' CANCER. RES. vol. 61, no. 8, 2001, pages 3225 - 3229, XP002982492
GERDES B. ET AL.: 'P16 INK4alpha alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer' SURGERY vol. 129, no. 4, 2001, pages 490 - 497, XP002982493

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).